Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above 200-Day Moving Average – Time to Sell?

Shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $46.19 and traded as high as $50.43. Global X Genomics & Biotechnology ETF shares last traded at $48.56, with a volume of 6,369 shares changing hands.

Global X Genomics & Biotechnology ETF Price Performance

The company has a 50-day moving average price of $45.94 and a two-hundred day moving average price of $46.19. The company has a market cap of $54.39 million, a PE ratio of -20.75 and a beta of 1.21.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of GNOM. U.S. Capital Wealth Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF during the fourth quarter valued at approximately $575,000. IFP Advisors Inc raised its stake in Global X Genomics & Biotechnology ETF by 20.8% during the third quarter. IFP Advisors Inc now owns 2,835 shares of the company’s stock valued at $110,000 after buying an additional 489 shares in the last quarter. Bank of America Corp DE raised its stake in Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock valued at $5,240,000 after buying an additional 48,394 shares in the last quarter. Jane Street Group LLC raised its stake in Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares in the last quarter. Institutional investors and hedge funds own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.